ATE137410T1 - Konjugate von ''pokeweed'' antiviralem protein und monoklonalen antikörpern - Google Patents

Konjugate von ''pokeweed'' antiviralem protein und monoklonalen antikörpern

Info

Publication number
ATE137410T1
ATE137410T1 AT90911551T AT90911551T ATE137410T1 AT E137410 T1 ATE137410 T1 AT E137410T1 AT 90911551 T AT90911551 T AT 90911551T AT 90911551 T AT90911551 T AT 90911551T AT E137410 T1 ATE137410 T1 AT E137410T1
Authority
AT
Austria
Prior art keywords
pokeweed
conjugates
antiviral protein
monoclonal antibodies
protein
Prior art date
Application number
AT90911551T
Other languages
English (en)
Inventor
Fatih M Uckun
Joyce Mintzer Zarling
Original Assignee
Univ Minnesota
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Oncogen filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE137410T1 publication Critical patent/ATE137410T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90911551T 1989-07-25 1990-07-12 Konjugate von ''pokeweed'' antiviralem protein und monoklonalen antikörpern ATE137410T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30

Publications (1)

Publication Number Publication Date
ATE137410T1 true ATE137410T1 (de) 1996-05-15

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911551T ATE137410T1 (de) 1989-07-25 1990-07-12 Konjugate von ''pokeweed'' antiviralem protein und monoklonalen antikörpern

Country Status (17)

Country Link
EP (1) EP0441917B1 (de)
JP (1) JP3109678B2 (de)
KR (1) KR920700698A (de)
AT (1) ATE137410T1 (de)
AU (1) AU631674B2 (de)
CA (1) CA2037900C (de)
DE (1) DE69026812T2 (de)
DK (1) DK0441917T3 (de)
ES (1) ES2087158T3 (de)
FI (1) FI911447A0 (de)
GR (1) GR1002180B (de)
IE (1) IE74143B1 (de)
IL (1) IL95134A (de)
NO (1) NO911174L (de)
NZ (1) NZ234607A (de)
PT (1) PT94789B (de)
WO (1) WO1991001145A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (de) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives

Also Published As

Publication number Publication date
AU631674B2 (en) 1992-12-03
KR920700698A (ko) 1992-08-10
IE74143B1 (en) 1997-07-02
FI911447A7 (fi) 1991-03-25
DE69026812T2 (de) 1996-11-28
WO1991001145A1 (en) 1991-02-07
JP3109678B2 (ja) 2000-11-20
PT94789A (pt) 1991-03-20
EP0441917A1 (de) 1991-08-21
NO911174D0 (no) 1991-03-22
PT94789B (pt) 1997-04-30
CA2037900A1 (en) 1991-01-26
CA2037900C (en) 1999-11-16
IE902593A1 (en) 1991-02-27
AU6140590A (en) 1991-02-22
JPH04502625A (ja) 1992-05-14
GR900100550A (el) 1991-12-10
NZ234607A (en) 1992-10-28
IL95134A0 (en) 1991-06-10
FI911447A0 (fi) 1991-03-25
DE69026812D1 (de) 1996-06-05
DK0441917T3 (da) 1996-09-16
GR1002180B (en) 1996-03-11
EP0441917B1 (de) 1996-05-01
ES2087158T3 (es) 1996-07-16
NO911174L (no) 1991-05-24
IL95134A (en) 1996-01-31

Similar Documents

Publication Publication Date Title
EP1035132A4 (de) Monoklonale antikörper zur apoptosis-induzierung
DE3585087D1 (de) Retrovirale polypeptide in zusammenhang mit menschlicher transformation.
DE69635377D1 (de) Effiziente anreicherung und detektion von ausgesäten tumorzellen
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
DK282987A (da) Lagdelt immunoanalyseorgan til bestemmelse af et antigens tilstedevaerelse, og hvori der anvendes antistoffer beregnet til transport af partikler
DK98187D0 (da) Monoklonale antistoffer og antigen for human ikke-smaacellet lungecarcinoma og visse andre typer human carcinoma
EP0600326A3 (de) Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper.
DE69026812D1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
DE69231495D1 (de) Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
AU8944291A (en) Immunoassay for the determination of anti-hiv antibodies in human samples
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DK0442372T3 (da) Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays
ATE2048T1 (de) Isolierung von hepatitis be-antigen.
DK314886D0 (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
AU6257486A (en) Specific mycoplasma membrane antigen and antibody and their clinical applications
FI914924A7 (fi) Monoklonaalinen vasta-aine suomusolukarsinooma-antigeenien erottamisee n ja menetelmä sen käyttämiseksi
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
FR2610308B1 (fr) Pont aiguilleur pour le transfert et le tri d'articles
NO922878D0 (no) Noeytralisering og/eller adcc-formidlende monoklonalt hiv-antistoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee